1186400-76-9

Basic information

• Product Name: benzyl-2-(4-methoxyphenylthio)ethylcarbamate
• Synonyms: benzyl-2-(4-methoxyphenylthio)ethylcarbamate
• CAS NO: 1186400-76-9
• Molecular Weight: 317.409
• Mol File: 1186400-76-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: benzyl-2-(4-methoxyphenylthio)ethylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl-2-(4-methoxyphenylthio)ethylcarbamate(1186400-76-9)
• EPA Substance Registry System: benzyl-2-(4-methoxyphenylthio)ethylcarbamate(1186400-76-9)

Safety Data

• Hazardous Substances Data: 1186400-76-9(Hazardous Substances Data)

Upstream product

• 696-63-9 4-Methoxybenzenethiol 
• 36155-36-9 2-<(4-methoxyphenyl)thio>-1-aminoethane 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 1186400-77-0 benzyl 7-methoxy-2,3-dihydrobenzo[f][1,4]-thiazepine-4(5H)-carboxylate 
• 145903-31-7 7-methoxy-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine 
• 1467605-60-2 methyl-3-((7-methoxy-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)methyl)benzoate 
• 1467605-68-0 3-((7-methoxy-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)methyl)benzoic acid 

Relevant articles and documents

Synthesis of 2,3,4,5-Tetrahydrobenzo[1,4]thiazepines via N-Acyliminium Cyclization

We report an efficient and scalable synthesis of 7-methoxy-2,3,4,5-tetrahydrobenzo[1,4]thiazepine, the core structure of biologically active molecules like JTV-519 and S107. This synthetic route, starting with 4-methoxythiophenol and proceeding via acyliminum cyclization, gives the target product in four steps and 68% overall yield and is a substantial improvement over previously published processes. Nine additional examples of tetrahydrobenzo[1,4]thiazepine synthesis via acyliminium ring closure are also presented.

Agents for treating disorders involving modulation of ryanodine receptors

The present invention relates to 1,4-benzothiazepine derivatives and their use to treat conditions, disorders and diseases associated with ryanodine receptors (RyRs) that regulate calcium channel functioning in cells. The invention also discloses pharmaceutical compositions comprising the compounds and uses thereof to treat diseases and conditions associated with RyRs, in particular cardiac, musculoskeletal and central nervous system (CNS) disorders.